To determine whether serum vitamin D levels were related to the risk of anxiety and depression among patients with chronic obstructive pulmonary disease (COPD), as well as their spirometry parameters, disease severity, and other clinical findings.
Introduction
Chronic obstructive pulmonary disease (COPD) is a quite frequent, preventable, and treatable lung disease characterized by persistent respiratory symptoms and airway obstruction that develops upon exposure to harmful gasses or particles. Exacerbations and coexisting comorbidities contribute to disease severity [1] . It is one of the leading causes of morbidity and mortality worldwide and is a significant economic and social burden [2, 3] .
COPD most commonly emerges in middle aged or elderly individuals, often coexisting with other medical conditions, the most common of which are skeletal muscle weakness, malnutrition and other eating disorders, cachexia, cardiovascular diseases, endocrine abnormalities, anemia, anxiety and depression, as well as lung cancer. Comorbidities affect COPD severity and prognosis negatively [4] .
Although anxiety and depression are common among patients with COPD, they are mostly untreated. Factors that contribute to anxiety and depression among patients with COPD are physical disability, long-term oxygen support requirement, low body mass index (BMI), severe dyspnea, % of predicted forced expiratory volume in 1 second (FEV1) below 50 and existing comorbidities [5] .
A workshop report published in 2008 reported the prevalence of anxiety as 10-19% and depression as 10-42% among patients with COPD [5] . Other studies similarly documented a higher prevalence of anxiety and depression in patients with COPD when compared with the normal population [6, 7] .
Studies that investigated the relation between the degree of pulmonary functional deterioration and anxiety and depression revealed no correlation between % of predicted FEV1 and the psychologic aspect of the disease. On the other hand, it has been shown that the presence of respiratory symptoms leads to severe anxiety and depression, and the presence of dyspnea is significantly correlated with anxiety and depression [8, 9] .
Results from studies that investigated the relation between serum vitamin D levels and the presence of anxiety and depression are conflicting. One study revealed that low serum vitamin D levels were associated with an increased prevalence of depression; however, an intervention of vitamin D replacement had no effect on symptoms of depression [10, 11] . Another study revealed that patients with depression had lower serum vitamin D levels (P=0.001), which were inversely correlated with symptom severity [12] . Another study by Zhao et al., found no significant correlation between serum vitamin D levels and depression [13] .
In this study, we aimed to determine whether serum vitamin D levels were related to the risk of anxiety and depression, as well as severity of symptoms, COPD stage, and other clinical properties.
Patients and Methods
The study was conducted in Marmara University Medical School, Department of Pulmonary and Critical Care Medicine, after being approved by the local ethics committee. Ninety-two patients who were admitted to outpatient clinics between November 1st, 2013, and February 28th, 2014, and were diagnosed as having COPD through pulmonary function test criteria of FEV1 to forced vital capacity (FVC) ratio was less than 0.70 and negative reversibility tests, who had no history of exacerbation within the previous month, and were aged over 18 years, were included in the study.
The included patients provided written consent, performed spirometry, and their modified Medical Research Council (mMRC) dyspnea scale and COPD Assessment Test (CAT) scores were calculated. Their COPD exacerbation numbers were questioned and combined COPD groups were determined [1] .
In accordance with the American Thoracic Society (ATS) criteria, spirometry testing was performed three times via an MIR Spirolab II (Medical International Research (Rome, Italy Serial No: 149491103403) device and the best of the three measurements was recorded [14] . Reversibility was tested after inhalation of 4 puffs (400 micrograms) of salbutamol and repetition of the test 15 minutes later to measure FEV1 (% and liter [lt]), FVC (% and lt) and FEV1/ FVC (%). Severities of dyspnea were stratified from 0 to 4 using the mMRC scale [15] . The validated Turkish version of the CAT was applied to determine the level of symptom severity [16] .
The risk of anxiety and depression was determined using the validated Turkish version of the HADS questionnaire [17] , which consists of 14 questions where odd-numbered questions are related with anxiety and even-numbered questions are concerned with depression. HADS is a fourpoint Likert scale and a form of self -report where each item is graded from 0 to 3. The Turkish version of the scale has a cut-off of 10 points for anxiety and 7 points for depression.
Patients with scores above these thresholds were considered to be in risk groups.
When calculating Body mass index, airflow Obstruction, Dyspnea and Exercise capacity (BODE) indices, the factors taken into account were BMI, % of predicted FEV1 from pulmonary function tests, mMRC scores, and 6-minute walk distance [18] . The 6-minute walk test was performed according to the ATS recommendations [19] .
Statistical Analysis
All statistical analyses were performed using version 17.0 of SPSS. Categorical variables were compared using the Chi-square test and Fisher's exact test. Chi-square test was used for 2x2 contingency tables. Normally distributed variables were analyzed using One-way ANOVA and variables that were not distributed normally were analyzed using the Kruskal-Wallis test. Correlation analyses were run using Pearson's correlation test for normally distributed data, and Spearman's correlation test for those that were not. In all analyses, a P value <0.05 was considered as significant.
Results
Ninety-two stable patients with COPD were included in the study. Eighty-one (88%) of the participants were male and 11 (12%) were female, and the mean age was 61.5±10.5 years. When distributed among the combined COPD assessment groups, 31 (33.7%), 41 (44.6%), 5 (5.4%), and 15 (16.3%) patients were placed in groups A, B, C, and D, respectively. The sociodemographic and clinical variables of the patients according to risks of anxiety and depression are presented in Table I .
According to the HADS scores, 16 (17.4%) and 29 (31.5%) patients were detected above the cut-off point for Figure 1 ). 
Discussion
At the end of this study, we found that patients with COPD who had low serum vitamin D levels had higher anxiety and depression scores when assessed with HADS. Furthermore, patients' anxiety and depression scores correlated positively with their symptom scores irrespective of their % of predicted FEV1 values. In accordance to these findings, the BODE index, which determines the clinical situation of the patients, was positively correlated to anxiety scores; however, this did not reach statistical significance.
In our study, the prevalence of anxiety and depression risk was found to be higher than in the normal population, consistent with other studies [5] [6] [7] [8] [9] . More importantly, our study established a negative correlation between anxiety and depression scores and serum vitamin D levels, as well as a positive correlation between symptom scores and anxiety risk between and depression scores. Furthermore, our study showed that a statistically significant difference in terms of anxiety risk between ABCD groups, exists more prominently in groups B and D.
Epidemiologic studies have revealed the emerging prevalence of vitamin D deficiency throughout the world and most prominently in North America and West Europe [20, 21] . There are no definitive data regarding vitamin D deficiency in Turkey; however, it is reported at between 30-75% [22] . Although, Turkey lies in an advantageous geographic location in terms of sunlight exposure, reasons such as dressing habits, inadequate consumption of vitamin D fortified foods, and a limited practice of outdoor activities leads to an increased prevalence of vitamin D insufficiency [23] . Many studies were performed about the prevalence of vitamin D insufficiency in patients with COPD. A study by Forli et al. determined a vitamin D deficiency prevalence of over 50% in their cohort of patients in line for lung transplantation, most of whom were diagnosed as having COPD [24] . Another cross sectional study by Franco et al. was conducted on 49 patients with COPD where only 3 (6%) had adequate (>30 ng/mL) levels of vitamin D; 29 (59%) had inadequacy (21-29 ng/mL) and 17 (35%) had deficiency (<20 ng/mL) [25] . Another study that was conducted on 462 patients with COPD found that 44.8% of the patients have inadequate levels of vitamin D and 30.5% were deficient [26] . In our study, the prevalence of vitamin D deficiency was quite high because 89.1% of the 92 patients studied were deficient and 7.6% had inadequate vitamin D levels; only 3 patients (3.2%) had sufficient levels of vitamin D.
Our study revealed vitamin D levels were correlated negatively with both anxiety and depression scores. Few studies have been conducted exploring the relation between levels of vitamin D and anxiety and depression; however, a study by Persson et al. revealed a statistically significant relationship between serum vitamin D levels and the presence of depression in 403 patients with COPD [27] .
Many studies conducted among patients with COPD showed that the prevalence of anxiety and depression was higher in patients with COPD when compared with the normal population. Parallel to the current medical literature, our study identified the prevalence of anxiety as 17.4% and depression as 31.5% in patients with COPD [5] [6] [7] [8] .
Pulmonary impairment in COPD and emotional responses secondary to respiratory diseases cause dyspnea and physical inability, which further cause physical deconditioning, and social isolation leading to anxiety and depression [28] . It is known that cigarette smoking, inflammation, and hypoxia have potential effects on the development of depression in patients with COPD but the most important predicting factors of depression are diminished quality of life and symptom severity [29] . Consistent with our findings a recent study reports higher anxiety and depression scores in more symptomatic patients with COPD [9] .
Our study did not yield a relation between % of predicted FEV1 and the risk of anxiety and depression; however, there are conflicting studies regarding the presence of a correlation [9, 30, 31] .
In addition to % of predicted FEV1 values, the BODE index evaluates the clinical status of the patients by taking symptoms and exercise capacities into account. In our study, the relationship between BODE indices and anxiety scores showed a positive correlation that approached but did not reach statistical significance. In the current medical literature, many studies demonstrated that the BODE index correlated better with anxiety and depression than % of predicted FEV1 [32, 33] .
The most important shortcoming of our study is its population size and the lack of a control group, which limits the comparison of anxiety and depression risk with the normal population. We may also assume the reason that the relation between BODE indices and anxiety and depression scores approached but could not reach statistical significance was the small sample size. Another limitation of the study is that we could only evaluate serum vitamin D levels during winter months; thus, could not take seasonal variances into account.
In conclusion, this study, which was conducted on a small number of patients, demonstrates serum vitamin D levels are very low in patients with COPD, and these low levels of vitamin D are negatively correlated with anxiety and depression scores. The high risk of anxiety and depression among patients with COPD should caution physicians to be more aware of these in the clinical setting. In addition, the positive correlation between anxiety and depression scores and symptom scores should alert us to consider the psychological comorbidities of the patients in terms of achieving better symptom control.
